Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04656847
Other study ID # IC4-05150-065-RUS
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date October 18, 2021

Study information

Verified date January 2022
Source Servier Russia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug for 12 weeks in the daily clinical practice. SPC will be used according to the approved instruction for medical use of the medicine. This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.


Description:

This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings. Baseline data will be collected retrospectively from medical records of stable CAD patients with HTN and a history of MI, including disease history of the patient. To be included in the study for further prospective observation a patient should have been administered bisoprolol/ perindopril SPC within first three months before the Index Date. (Fig.1). Therefore, criteria for non-inclusion or inclusion of the patient in the study are to be retrospectively evaluated by the investigator using recorded clinical data available from medical records. Once a physician makes decision to include a patient in the study and, in particular, on the prospective observation for 3 months, a visit to the clinic for obtaining signed patient's consent to participate in the study should be appointed and made within 1 month from the Index Date. Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program. Such studies are carried out in case of observational programs when the studied drug is administered in line with indications according to the instruction for its medical use. Several multicenter, non-interventional, open, incomparable studies have been performed with bisoprolol/perindopril SPC in patients with HTN and coronary heart disease. A total of 70 general practitioners and cardiologists from primary care facilities will participate in the program. Each doctor will include about 7-8 patients. In total, it is planned to include at least 500 patients.


Recruitment information / eligibility

Status Completed
Enrollment 486
Est. completion date October 18, 2021
Est. primary completion date October 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Patients with stable angina pectoris of class I-III according to the Canadian Cardiovascular Society (CCS) classification and a history of myocardial infarction no earlier (not less) than 3 months before inclusion in the study. HTN (including resistant* hypertension) - Signed informed consent to participate in the study. - Bisoprolol/ perindopril SPC prescription** within 3 month period before Index date Exclusion Criteria: - Hypersensitivity to bisoprolol, perindopril, excipients of the medicine, or other ACE inhibitors. - Any contraindication for bisoprolol/perindopril's SPC according to the instruction for medical use - CAD, angina pectoris of functional class IV according to the CCS classification (Appendix 1). - Chronic heart failure of class III-IV according to the New York Heart Association (NYHA) functional classification of heart failure (Appendix 3). - Cerebrovascular diseases (ischemic, haemorrhagic stroke, or transient ischemic attack) within the past 6 months prior to inclusion in the study. - A history of revascularization procedure within 3 months prior to inclusion in the study. - Hypertrophic obstructive cardiomyopathy. - Office BP = 180/110 mm Hg on treatment - Type 1 diabetes mellitus and decompensated type 2 diabetes mellitus. - Bradycardia with a heart rate of less than 60 beats per minute. - Atrioventricular block (II-III degree), sinoatrial block, or sick sinus syndrome. - Severe bronchial asthma or severe chronic obstructive pulmonary disease. - Arterial hypotension (BP less than 100/70 mm Hg). - Pregnancy, breastfeeding. - Secondary hypertension. - Severe decompensated diseases of organs and systems requiring continuous treatment. - Current participation in another clinical trial and within 30 days prior to signing informed consent.

Study Design


Intervention

Drug:
in daily everyday routine practice
patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.

Locations

Country Name City State
Russian Federation Peoples' Friendship University of Russia Moscow

Sponsors (1)

Lead Sponsor Collaborator
Servier Russia

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antihypertensive effectiveness (SBP and DBP reduction) of bisoprolol/perindopril SPC in CAD patients with previous MI and HTN at week 12 of treatment Change in the mean systolic and diastolic BP levels at week 12 of treatment with SPC compared with baseline among patients included in the study. 3 months
Secondary Change in mean systolic and diastolic BP levels at week 4 Change in mean systolic and diastolic BP levels at week 4 of treatment with SPC compared with baseline. 1 month
Secondary Change in number of angina attacks per week at week 4 Change in number of angina attacks per week at week 4 of treatment compared with baseline. 1 month
Secondary Change in number of angina attacks per week at week 12 Change in number of angina attacks per week at week 12 of treatment compared with baseline. 3 months
Secondary Proportion of patients who were taking lipid lowering therapy Proportion of patients who were taking lipid lowering therapy (LLT) at week 12 of treatment 3 months
Secondary Proportion of patients receiving LLT who achieved target levels of LDL Proportion of patients receiving LLT who achieved target levels of LDL C at week 12 of treatment. 3 months
Secondary SBP =140 mm Hg and DBP =90 mm Hg at week 4. Proportion of patients who achieved SBP =140 mm Hg and DBP =90 mm Hg at week 4. 1 month
Secondary SBP =140 mm Hg and DBP =90 mm Hg at week 12 Proportion of patients who achieved SBP =140 mm Hg and DBP =90 mm Hg at week 12 3 months
Secondary Younger than 65 who achieved SBP =130 mm Hg and DBP =80 mm Hg at week 4 of treatment Proportion of patients younger than 65 who achieved SBP =130 mm Hg and DBP =80 mm Hg at week 4 of treatment 1 month
Secondary younger than 65 who achieved SBP =130 mm Hg and DBP =80 mm Hg at week 12 of treatment Proportion of patients younger than 65 who achieved SBP =130 mm Hg and DBP =80 mm Hg at week 12 of treatment. 3 months
Secondary older than 65 years who achieved SBP=140 mm Hg and DBP =90 mm Hg at week 4 of treatment Proportion of patients older than 65 years who achieved SBP=140 mm Hg and DBP =90 mm Hg at week 4 of treatment 1 month
Secondary older than 65 years who achieved SBP=140 mm Hg and DBP =90 mm Hg at week 12 of treatment Proportion of patients older than 65 years who achieved SBP=140 mm Hg and DBP =90 mm Hg at week 12 of treatment 3 months
Secondary mean heart rate (HR) at week 4 Changes in the mean heart rate (HR) at week 4 of treatment compared with baseline 1 month
Secondary mean heart rate (HR) at week 12 Changes in the mean heart rate (HR) at week 12 of treatment compared with baseline 3 months
Secondary patients who achieved target level of resting HR (55-60 bpm) at week 4 Proportion of patients who achieved target level of resting HR (55-60 bpm) at week 4 of treatment. 1 month
Secondary patients who achieved target level of resting HR (55-60 bpm) at week 12 Proportion of patients who achieved target level of resting HR (55-60 bpm) at week 12 of treatment. 3 months
Secondary Changes in the quality of life assessed by Health Questionnaire EuroQol (EQ-5D-5L) at week 4 Changes in the quality of life assessed by Health Questionnaire EuroQol (abbreviated as EQ-5D-5L, scale is numbered from 0 to 100; 100 means the best health; 0 means the worst health) at week 4 of treatment compared with baseline 1 month
Secondary Changes in the quality of life assessed by Health Questionnaire EuroQol (EQ-5D-5L) at week 12 Changes in the quality of life assessed by Health Questionnaire EuroQol (abbreviated as EQ-5D-5L, scale is numbered from 0 to 100; 100 means the best health; 0 means the worst health) at week 12 of treatment compared with baseline 3 month
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A